All News

Article

Litifilimab in Cutaneous Lupus Erythematosus

Jack Cush, MD Apr 14, 2026

Biogen has announced positive results of their Phase 2 study, evaluating litifilimab in patients with active cutaneous lupus erythematosus (CLE), presented at the recent American Academy of Dermatology (AAD) Annual Meeting.

Article

Modest Benefits with AI Scribes on EHR Documentation

EurekAlert! Apr 14, 2026

Documenting a patient visit in the electronic health record (EHR) is essential to healthcare delivery, but also a major contributor to clinician burnout.

Article

Screening High Risk Myositis Patients for Cancer

Jack Cush, MD Apr 13, 2026

An Italian retrospective study of 411 idiopathic inflammatory myopathies (IIM) patients applied IMACS criteria to assess the risk of cancer and found significantly more cancers in those at high risk.

Article

Top Four and More (4.10.2026)

Jack Cush, MD Apr 10, 2026

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week - including his top four favorite subjects.

JAMA Guideline on the Management of Crohn Disease https://t.co/GV0lICS8Sn https://t.co/aFWH5Tl4Jv

JAMA Guideline on the Management of Crohn Disease | RheumNow

OL phase 2 study 50 active systemic JIA pts Randomized to IL-1 inhibitor, firsekibart or TCZ q2wk x 24 wks. At day 28, modified ACR Pedi 30response (no fever) favored FIRS 3mg dose (94% vs 75% vs 82%). Also higher ACR Pedi 70/90 responses & steriod tapers. https://t.co/8bdCLUFFLT https://t.co/ddQe7k25UE

https://buff.ly/xbTF6DM

Global Study of #gout - incidence increased by 158% (from 1990 to 2023), during which mean onset agerose from 58 to 62 years; but % young-onset gout dropped 15.8% to 9.8%. #s due to aging, not younger onset. https://t.co/5pqMwPEnuj https://t.co/414vJHnBYi

Global trends in age at onset of gout, 1990–2023: a sex-stratified and forecast…

2023 FDA’s removal of REMS in-person Rx requirement for mifepristone was assoc w/ large increase in mifepristone Rx at pharmacies (most thru mail order where abortion is legal and telehealth Rxing is permitted https://t.co/9NHMmxUpLl https://t.co/jkV5DmIaJt

Changes in Mifepristone Use at Pharmacies After Removal of the FDA In-Person Di…

Systematic review of plasma exchange (PE) in myositis (IIM) - 35 studies (mostly observational), 473 IIM pts (361 Rx w/ PE). Many reported improvements (publication bias). 7 comparative RCTs show no mortality benefit (severe ILD) (RR 0.41, 95% CI 0.16–1.06, I2 = 70%) https://t.co/ox0pdUL3Ek

Claims data 2,751 #AAV patients - 6.2% developed #PJP infx. w/ predictors: age, max GC dose, rituximab, CTX, & PJP prophylaxis had Good concordance (0.70) @2mos & 0.66@1yrs. W/ monthly risk of 1.0%, prophylaxis yielded 34 potentially preventable PJP cases https://t.co/c2ObDnmfYp https://t.co/0JRd1k0R2R

Development of a time-dependent prediction model for the risk of Pneumocystis j…

“Math has no opinion” - Mellody Hobson

Couldn’t attend https://t.co/4UQlqwujiR 2026? You can now watch the entire meeting On Demand. This high-impact program features leading experts discussing: • RA outcomes and pathogenesis • Obesity, inflammation, and rheumatic disease • Treatment decisions in Psoriatic https://t.co/A3wb3pzbl3

RheumNow

Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis The original CRA/SPARCC recommendations endorsed IL-17i and TNFi as equivalent second-line options for adults with active axSpA who fail an adequate NSAID trial. JAK inhibitors were reserved for patients with prior https://t.co/e1iLSksgYj

Danish real-world study anifrolumab use in 36 #SLE pts. SLEDAI-2K decreased from 8 (baseline) to 2 @ mos 3; @6 mos 52% had SLEDAI-2K=0. 87% had PGA ≤0.5 w/ LLDAS, & 70% DORIS remission. Pred use declined by >50%. Herpes infx were most freq AE https://t.co/gNIAoXplMt https://t.co/D6xhQrY8ep

Real-world use of anifrolumab in systemic lupus erythematosus: A retrospective …

UK Our Future Health study of 1,563,155 finds affective Dz (depression, bipolar, anxiety) signific higher (p<0.001)in autoimmune pts vs gen. pop. (29% vs 18%) - dx by PHQ-9, GAD-7. (OR 1.86), even after adjustments income and pain, etc. https://t.co/HoKBeAZxbS https://t.co/NtJhaf7WCo

Affective disorders and chronic inflammatory conditions: analysis of 1.5 millio…

ILD in RA – Dr. Jeffrey Sparks In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Jeffrey Sparks reviews the latest advances shaping diagnosis and management of ILD in RA. 🎧 Listen here: https://t.co/U5cZVlgAka #Rheumatology #ILD #RNL2026 https://t.co/LidiS3Wj9d

Italian retrospective study 411 IIM pts classified cancer risk per IMACS criteria: 44% high-, 38% intermed- 18% standard-risk. 9.2% had CA w/in 3yrs. Signif more in high-risk (OR 4.05). CA predictors: TIF1γ (OR 12.3), SAE1 (OR = 11.9) https://t.co/j4gA0g79bI https://t.co/Pt5nMs89bl

Real-world application of the international myositis assessment and clinical st…

COMMON - Incidental Rotator Cuff Abnormalities on MRI In this cross-sectional study of 602 Finnish adults undergoing bilateral shoulder magnetic resonance imaging (MRI) and clinical assessment, abnormalities were found in nearly everyone over age 40 years, regardless of whether https://t.co/2n58lglVP0

Advanced Practice Rheum: Methotrexate In this session, we're going to review methotrexate. It is the most popular of disease-modifying drugs used in rheumatology. While it may be indicated for a few disorders, it's widely used in many inflammatory and autoimmune disorders. https://t.co/RKh3mQv7Hx

Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had MC-A (rash 1055; alopecia 731; m ulcers 352); 15% persistently. MC-A assoc w/ W, smoking, +serologies, vasculitis, myositis, serositis, nephritis, NP-SLE https://t.co/XeBc4DJon9 https://t.co/n2wAq2OIGt

Mucocutaneous disease activity and damage accrual in systemic lupus erythematos…

Topics

All News

Litifilimab in Cutaneous Lupus Erythematosus

Modest Benefits with AI Scribes on EHR Documentation

Screening High Risk Myositis Patients for Cancer

Top Four and More (4.10.2026)

Do you get our email newsletter?